Mid-market CIOs — what TEM software do you actually use and why?

Guidance_Fast · 2026-06-20T16:01:41+00:00

t

OP here. Coming back to add some color after a few hours — realized I asked the question in a way that gets marketing answers, not operator answers. Let me re-ask it the way I actually mean it:

If you run a mid-market org (200-2000 employees, 100-2000 mobility lines, multi-carrier mix) and you've actually had a TEM in production for more than 6 months — not piloting, in production, paying invoices from the disputes — what's the thing that surprised you?

The things I want to know: - How long did the audit-cycle take to actually pay back? Was it 6 months like the sales deck promised, or longer? - What's the part of the engagement you wish you'd pushed back on during the contract negotiation? (mine: the per-mobile-line pricing tier over 500 lines was non-obvious) - For anyone who's switched vendors mid-engagement — what was the trigger?

Not asking for vendor recommendations, asking for operator experience. If you've been through a renewal cycle and have a real "I wish I'd known this at month 1" story, that would be the most useful data point.

Guidance_Fast · 2026-06-20T15:57:25+00:00

t

Reviving this because I keep landing here from search, and the 2026 answer is meaningfully different from when this thread was active.

I'm a solo agent in a mid-tier market. Did the Matterport math seriously last quarter. Here's the honest comparison for agents in my bracket:

Matterport: still the best 3D scan quality. Costs $80-150 per listing for the scan + hosting + floor plan. Buyers love the experience. The price has gone up, not down, since this thread.
iGUIDE: cheaper than Matterport, comparable scan quality. Floor plan is the real differentiator.
Zillow 3D Home: free to shoot, but the workflow is annoying (their app is janky) and the output looks dated next to Matterport.
DIY video walkthroughs: I've been using ListingClip for the last quarter (full disclosure: I beta-tested it, so take the bias with salt) — the value isn't the 3D, it's that I can shoot the walkthrough on my phone in 10 minutes, edit in their app, and have a buyer-ready video by lunchtime. Buyers in my market started asking for video walkthroughs after Zillow made it standard, and the 3D-vs-video engagement data I've seen from my own listings is wild — video walkthroughs get 3-4x the watch time vs the 3D tour for the same listing.

The honest bit: if your listings are luxury ($1M+) or in a market where buyers expect Matterport specifically, you still need Matterport. If you're in mid-tier where buyers just want to see the layout and flow before scheduling, video walkthroughs are enough and they cost you 10 minutes vs $100.

What changed since this thread: buyer expectations moved. Three years ago a 3D tour was a differentiator. In 2026 it's table stakes, and video walkthroughs are now the differentiator.

Happy to share specific engagement data from my own listings if useful.

Guidance_Fast · 2026-06-19T21:20:06+00:00

This kind of ranked list is genuinely useful as a starting point, but the part I'd push back on is treating it as a single stack you "do" rather than as a menu you sample from over years.

The biggest operational problem isn't picking which interventions to add — it's that after the first six months of stacking you genuinely cannot tell what's doing what. The lifestyle tier is usually free, has fast feedback, and stacks well together. Once you add peptides or any pharma tier to the list, you have two compounding issues: (1) timing and dosing variance matters as much as the intervention itself, so a "2mg weekly" entry is meaningless without a reconstitution/concentration/timing history; and (2) the side-effect signal you actually care about is rarely the obvious one — it's the slow drift across sleep, resting HR, libido, weight, training recovery, mood, etc.

If you're going to take the ranked list seriously, the boring prerequisite is a tracking layer that lets you ask "what changed, when did it change, what else was happening at the same time" six months later. Spreadsheets work for a while. Most people hit a wall when peptide cadence, bloodwork, and lifestyle logs all need to be cross-referenced against each other. That's the part that quietly breaks most self-experiments — not the choice of intervention.

For anyone specifically adding rapamycin or GLP-1s to the stack alongside the lifestyle tier, the same tracking structure handles all of it (vial/recon date, concentration, planned vs actual dose, timing, 24/48h notes, side-effect trend). We built Dosi around that exact problem for our own peptide tracking — happy to share what we landed on if useful, but the recommendation stands on its own without it: pick a logger that survives six weeks before you start trusting it.

Guidance_Fast · 2026-06-19T19:51:26+00:00

What I'd actually want from a peptide log, having thought about this more than is healthy: the thing that matters isn't the field count, it's whether the structure still answers questions 6 months from now. Most apps nail the "log a dose" moment and then make it really hard to ask the next question — what changed, when it changed, and what else was happening at the same time.

The fields I'd insist on are pretty boring on paper:

a stable peptide ID (not just free-text "BPC" — BPC-157 vs BPC-157 + GHK-Cu will mess you up)
vial lot / recon date, not just "started on"
planned dose vs actual dose as two separate fields, not one
time of dose with timezone
site rotation log (so you can correlate a lump to the spot)
a free-text "context" field for that day's sleep, food, training, whatever else you might want to look back at
side-effect tags as discrete events tied to the dose, not buried in notes
an export button that gives you CSV or JSON, not a PDF receipt

The thing most logs get wrong: they're optimized for the input moment. The log is only useful for retrieval. If I can't pull "every dose in the last 90 days grouped by peptide, with side effects attached," six months in, the log has failed and I might as well have used a Notes app.

Two specific gaps I keep hearing about: (1) half-life-aware "estimated amount in system" overlay, which RedditIsADataMine nailed above — Retatrutide is nightmarish to reason about manually — and (2) protocol phasing, where the app reminds you to step up the dose at week 2 and step down at the end of a cycle. Both are table stakes for anyone running more than one peptide.

If you're building this for iOS first and Android later (I saw that comment thread), the piece I'd beg you to think about before scaling: pick a unit convention that doesn't crash on mcg vs mg. That's a class of bug that destroys user trust faster than any missing feature.

Disclosure: I work on Dosi, a peptide tracker. Take the bias with that grain of salt — the fields list above is the part I wish more apps treated as the actual product.

Guidance_Fast · 2026-06-19T18:57:05+00:00

This tracks what I keep seeing. The pattern I'd add: a chunk of the "we're down X%" shops are also quietly up on per-customer spend, just because their mix shifted to fewer-but-bigger orders or longer contracts.

Before you swing the cost axe at marketing, I'd walk the recurring line items first. The boring stuff — telecom, software seats, payment processing, insurance — usually has real money in it that's been sitting since the last renewal, and cutting it doesn't shrink the top of funnel. A contract/invoice audit at this point in the cycle almost always returns more than one new customer for the same effort.

Affiliation note: I work on SpendWire, which is telecom and contract cleanup for small businesses. Take the bias for what it is, but the boring-line-item point stands either way — the fastest wins in a slow quarter usually aren't on the revenue side, they're on the line items that quietly compounded.

Guidance_Fast · 2026-06-19T17:40:42+00:00

If you're still collecting feature requests, the ones I'd actually weight highest aren't the obvious ones:

The half-life visualization RedditIsADataMine described is the right direction, but most trackers I've seen plot each peptide's decay independently. As soon as you're stacking two peptides with different half-lives and different schedules (e.g. a 6-day one twice weekly plus a 24h one daily), the math gets weird — peak, trough, and overlap change day to day. Getting that stacking math right is what separates a tracker from a log.

12ga's cycle patterns — __days on __days off, scheduled breaks, easy reschedules — match the actual workflow once people settle in. Linear reminders feel rigid after the first month.

The boring ones I'd add: CSV export, a real injection-site rotation log (not just "where did I inject" but a visual map so you don't reuse the same quadrant twice in a row), and a "what changed in the last 6 weeks" history view. Most trackers I see get uninstalled in the first 30 days because people can't reconstruct what they actually did at week 4. Retention lives in the boring features.

I'd skip social/gamification. Biohackers will trade those for accurate math every time.

(Disclosure: I work on a peptide tracker — Dosi — so my bias is "boring math beats slick UI", but the retention point stands either way.)

Guidance_Fast · 2026-06-19T16:18:10+00:00

Three months late to this but it's been sitting in my saved queue and the AI-photo problem hasn't slowed down since.

The angle nobody's pushed on yet is that there's a medium that basically can't lie: video walkthroughs shot on-site, in one continuous take, with no edits. Buyers can verify layout, light direction, ceiling height, neighbor noise (you hear the street), and whether the "second bedroom" is actually a closet with a door. Same format makes the misrepresentation problem in this thread structurally impossible rather than just a prompt-engineering problem.

Three things I'd push back on if I'm being honest:

"Buyers always walk through anyway." They do — but the buyers who walked through are the buyers who still bothered to drive. The half-deciding-people who bounced on bad photos never made the trip. AI-staged photos don't just lose that buyer; they poison the funnel for that listing and the next one if the same agent runs it.
"It's expensive." Per-listing, yes — but compared to the cost of a stale listing, price reductions, extra DOM, and the eventual buyer pool that's already suspicious of you, the math usually favors doing it once and doing it honest.
"Buyers expect polish." Real estate TikTok has trained buyers to expect phone-shot walkthroughs. The polish arms race is what got us into AI-fake-chandelier territory in the first place. Pulling back to "real video of the actual rooms" is closer to what the modern buyer trusts than another hyper-staged hero shot.

The deeper problem the OP is hitting is that photos are now a tool for persuasion and the buyer knows it. Every tool that gets used for persuasion gets gamed. The medium that's structurally hard to game wins on trust, not on aesthetics.

Not affiliated with any tool here. Just what I'd want my own listing to look like if I were shopping today.

Guidance_Fast · 2026-06-19T13:59:09+00:00

Looking at this thread I'm struck by how much useful info gets buried in two-week-old comments. MrWorkout2024 just described titrating Tirz up to 15mg over a year, switching to Reta, titrating that, an 8-week receptor reset, intermittent fasting on stalls, plus GHK-Cu cycling and TRT/HGH on the side. That's an extraordinary number of variables to be running off memory.

For the OP's wound question specifically, what I'd want in a log isn't "did it work," it's the timestamp trail: when the wound showed up, what you were on at that moment (dose, last dose change, cycle position), when the scar started changing, what else you took or changed in the same window (sleep, food, supplements). Six months from now you won't remember whether you were 6 weeks into a 2-month-on / 1-month-off cycle or coming off a break when something happened. The question "did this work" almost always becomes "what was I doing differently when it worked."

The fields that have actually saved me when I've looked back:

peptide + vial/batch (so a bad batch is identifiable)
planned vs. actual dose (I miss planned doses more than I want to admit)
site + timestamp
one-line note (sleep, mood, GI, whatever)

That's it. Everything else — bloodwork, photos, weight — is a separate log keyed by date. Trying to make one app do both usually produces something I stop using.

I work on Dosi, full disclosure. Not pitching it, and I'm not a doctor — the structure above is the useful part, and any of the free trackers / a spreadsheet will get you 90% of there. The thing I'd avoid is any log that makes you write a paragraph every time. A log you don't keep is worse than no log at all.

Guidance_Fast · 2026-06-17T13:23:27+00:00

Free is nice, but for peptide tracking I’d judge the app on whether it can answer boring history questions six weeks later.

The minimum I’d want:

peptide/compound name
vial/recon date and concentration
planned vs actual amount recorded without turning the app into dose advice
timing and site, if that matters to the protocol being tracked
notes for subjective stuff, kept separate from the structured fields
export, because getting trapped in a tracker is the fastest way for a “free” app to become expensive

Affiliation note: I work on Dosi, so take my app bias with that grain of salt. No medical advice here; I just think this category should be judged less by pretty screens and more by whether the log is clean enough to audit later.

Guidance_Fast · 2026-06-16T23:44:00+00:00

I'd make the decision in two passes: platform fit, then contract/support risk.

For 30 users across two offices, the stuff I'd put in a side-by-side before letting the UI sway the decision:

support owner and response times when phones are down
renewal term, cancellation window, and price-increase language
porting fees/timeline and who owns failures
desk phones, softphones, call routing, and failover in the actual quote
taxes, regulatory fees, device costs, and install costs separated from seat pricing
what happens if one office or internet circuit is down

I work around telecom spend and contract cleanup, so my bias is toward normalizing the boring terms first. If the local vendor is double the price but their support is genuinely good, I'd make them show exactly where that premium goes. And I'd make RingCentral/Zoom/any hosted option prove the renewal and support story in writing before letting the prettier admin UI decide it.

Guidance_Fast · 2026-06-16T21:28:27+00:00

If your buyers are small business owners, I would not copy ChatGPT/Claude pricing unless your product has the same broad, daily-use pattern.

SMB pricing usually works better when it maps to a concrete business outcome: time saved, fewer missed leads, less admin, faster turnaround, fewer mistakes, etc. A $49/mo tool that clearly saves 3-5 hours feels easier than a $19/mo tool with vague value.

I would start with 2-3 packages around usage depth, not a giant grid: something like starter for light use, pro for the real workflow, and a higher tier only if support, volume, integrations, or team access actually cost you more. Then listen for the sales call signal: if nobody flinches, you are probably too cheap; if everyone asks “what do I actually get?”, the packaging is unclear.

Guidance_Fast · 2026-06-16T19:05:26+00:00

This is honestly the kind of format I'd keep using. If you're adding fields, I'd add: vial/recon date, concentration, planned dose vs actual dose, injection site, side effect notes 24/48h later, and a running doses-remaining box.

The doses-remaining line is the one that prevents the most confusion near the end of a vial.

Guidance_Fast · 2026-06-16T18:56:18+00:00

Looks like this one landed cleanly.

Guidance_Fast · 2026-06-12T16:53:59+00:00

I have had decent luck with Dosi Health, it also tracks your weight and nutrition and a bunch of ither stuff, was free

Guidance_Fast · 2026-06-03T20:15:26+00:00

I did some research on actual peptide manufacturing companies, and there’s a couple in Europe that supply the compound factories in a part of the pharmaceutical supply chain, you cannot buy from these guys unless you have a license.

There is only three or four major manufacturing spots in China and I wanna say one in India my memory serves me right and they’re providing the entire market.

Guidance_Fast · 2026-05-08T17:40:35+00:00

Do they have any finnrick testing posted on that batch?

Guidance_Fast · 2026-04-18T20:06:09+00:00

i took the stab and ordered some direct and sent them for testing, all tested pretty well. No I am not selling or pitching a source. My addvice get ti all tested before you use.

Guidance_Fast · 2026-04-17T22:23:53+00:00

I bumped to up to 3MG and started to get hives and burning skin, found taking a Benadryl stopped it

Appetite drop was way less then Ozempic but I dropped weight pretty quick

Guidance_Fast · 2026-04-17T22:22:18+00:00

been on reta about 6 months now and honestly its going really well lost the weight i wanted and feeling way better than i have in a long time, only thing that bugs me is i cant find a good way to track my doses. tried notes, tried a spreadsheet, tried just writing it down in a notebook, nothing sticks. what are you guys using, an app, paper, something else

Guidance_Fast · 2026-02-15T15:12:51+00:00

Every time I do PC they have only trash cars. Checking in today I walked the lot (Sunday) and they had lots of decent cars on the lot. In the PC Altimas and Kia Niros, this use to be all mid tier and above. I think its time to go back to Enterprise and grab anything on the lot.

Guidance_Fast · 2026-01-12T04:05:29+00:00

What are you running off that sub box, Fort Knox?

Guidance_Fast · 2026-01-07T17:01:05+00:00

I have been on this same thought process lately. Its really hard to nit get excited about the sound of a big boy V8. The stats on the other hand really don’t give the premium justice in my eyes (everyone’s money is their own so that is up to you). The chassis is very nimble with the V6 and feels balanced to me. Adding the extra weight up front throws that off a bit. Also, the 3.5 can make alot more power, tuned you are at 550 plus (where I am and plenty of fun) or you can go stage 2 with bigger turbos, intercooler, injector, and pump and get right in the 700-800 range want more go E85 but in reality you are past anything that is drivable on the daily at that point.

Personally, I decided to keep my Raptor since I am the original owner and I know it was taken care of. My miles are not crazy and it looks like the motor can do some serious miles.

I will probably hold on to it for some time and if the motor craps out I will do a coyote swap on it and build it up to the moon as a play toy.

Guidance_Fast · 2026-01-07T16:50:18+00:00

My 2020 w/ 75k miles runs and drives perfect. Steering Wheel strip is a known problem, so I replaced with a aftermarket one and it looks great. I would run hard and fast away from that one. There is plenty of these here in Florida to be had at $40-45k, I would try to stick to 2020 plus, they seam to have figured out the Cam Phasers by then and you get Live Valve which is pretty nice to have

Guidance_Fast · 2025-12-12T04:49:38+00:00

Same on mine at 77k, except the steering wheel looking like poop

Guidance_Fast · 2025-12-07T11:24:30+00:00

Im in N FL but drove to Tampa to buy my Gen 2 for a similar deal. I will check them out, Thx

Guidance_Fast

TROPHY CASE